CA Patent

CA3010236A1 — Compositions and methods for immune cell modulation in adoptive immunotherapies

Assigned to Fate Therapeutics Inc · Expires 2017-07-27 · 9y expired

What this patent protects

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK,…

USPTO Abstract

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA3010236A1
Jurisdiction
CA
Classification
Expires
2017-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Fate Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.